Clinical characteristics of patients enrolled in the study
| Characteristics . | Cohort 1 . | Cohort 2 . |
|---|---|---|
| (N = 26) . | (N = 7) . | |
| Histology, n(%) | ||
| Angioimmunoblastic T-cell lymphoma | 11 (42) | 1 (14) |
| PTCL, not otherwise specified | 7 (27) | 0 |
| Anaplastic large cell lymphoma, ALK– | 5 (19) | 1 (14) |
| Anaplastic large cell lymphoma, ALK+ | 1 (4) | 3 (43) |
| NK/T-cell lymphoma | 0 | 2 (29) |
| Enteropathy-associated T-cell lymphoma | 1 (4) | 0 |
| Monomorphic epitheliotropic intestinal T-cell lymphoma | 1 (4) | 0 |
| Prior regimen(s), n (%) | ||
| CHOEP | 13 (50) | |
| CHOP | 5 (19) | |
| EPOCH | 2 (8) | |
| CHOEP + lenalidomide | 2 (8) | |
| SMILE | 0 | 2 (29) |
| Others (CHOEP/ICE, CHOEP + HD-MTX, CHOP/CHOEP, CHOEP/CHEP, brentuximab vedotin, pralatrexate, R-EPOCH, R-CHOP, ICE) | 4 (15) | 5 (71) |
| Age at transplant, median (range) | 59 (37-73) | 59 (23-68) |
| Sex, n (%) | ||
| Male | 16 (62) | 2 (29) |
| Female | 10 (38) | 5 (71) |
| Disease status at transplant, n (%) | ||
| Complete response | 23 (88) | 6 (86) |
| Partial response | 3 (12) | 1 (14) |
| Median time from AHCT to first romidepsin, d (range) | 75 (42-102) | 49 (44-80) |
| Total doses of romidepsin, median (range) | 21 (1-33) | 8 (2-32) |
| Characteristics . | Cohort 1 . | Cohort 2 . |
|---|---|---|
| (N = 26) . | (N = 7) . | |
| Histology, n(%) | ||
| Angioimmunoblastic T-cell lymphoma | 11 (42) | 1 (14) |
| PTCL, not otherwise specified | 7 (27) | 0 |
| Anaplastic large cell lymphoma, ALK– | 5 (19) | 1 (14) |
| Anaplastic large cell lymphoma, ALK+ | 1 (4) | 3 (43) |
| NK/T-cell lymphoma | 0 | 2 (29) |
| Enteropathy-associated T-cell lymphoma | 1 (4) | 0 |
| Monomorphic epitheliotropic intestinal T-cell lymphoma | 1 (4) | 0 |
| Prior regimen(s), n (%) | ||
| CHOEP | 13 (50) | |
| CHOP | 5 (19) | |
| EPOCH | 2 (8) | |
| CHOEP + lenalidomide | 2 (8) | |
| SMILE | 0 | 2 (29) |
| Others (CHOEP/ICE, CHOEP + HD-MTX, CHOP/CHOEP, CHOEP/CHEP, brentuximab vedotin, pralatrexate, R-EPOCH, R-CHOP, ICE) | 4 (15) | 5 (71) |
| Age at transplant, median (range) | 59 (37-73) | 59 (23-68) |
| Sex, n (%) | ||
| Male | 16 (62) | 2 (29) |
| Female | 10 (38) | 5 (71) |
| Disease status at transplant, n (%) | ||
| Complete response | 23 (88) | 6 (86) |
| Partial response | 3 (12) | 1 (14) |
| Median time from AHCT to first romidepsin, d (range) | 75 (42-102) | 49 (44-80) |
| Total doses of romidepsin, median (range) | 21 (1-33) | 8 (2-32) |
EPOCH, etoposide, prednisone, doxorubicin, cyclophosphamide, and vincristine; HD-MTX, high-dose methotrexate; ICE, ifosfamide, carboplatin, and etoposide; NK, natural killer cell; SMILE, dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide.